These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16546533)

  • 41. [In what way and how intensively should blood pressure be lowered in diabetic nephropathy?].
    Krämer BK; Wieçek A; Ritz E
    Dtsch Med Wochenschr; 1997 Jun; 122(25-26):829-32. PubMed ID: 9244671
    [No Abstract]   [Full Text] [Related]  

  • 42. [Renin-angiotensin system antagonists associated with reduced [corrected] mortality in diastolic heart failure].
    Edner M; Lund LH
    Lakartidningen; 2013 Feb 13-19; 110(7):331. PubMed ID: 23513377
    [No Abstract]   [Full Text] [Related]  

  • 43. The CARI guidelines. Cost-effectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes.
    Chadban S; Howell M; Twigg S; Thomas M; Jerums G; Cass A; Campbell D; Nicholls K; Tong A; Mangos G; Stack A; MacIsaac RJ; Girgis S; Colagiuri R; Colagiuri S; Craig J;
    Nephrology (Carlton); 2010 Apr; 15 Suppl 1():S195-203. PubMed ID: 20591031
    [No Abstract]   [Full Text] [Related]  

  • 44. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.
    Azizi M; Ménard J
    Circulation; 2004 Jun; 109(21):2492-9. PubMed ID: 15173039
    [No Abstract]   [Full Text] [Related]  

  • 45. Comment on: The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D?
    Alsaeed A
    Saudi Med J; 2021 Jan; 42(1):115. PubMed ID: 33399181
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current issues with dual inhibition of the renin-angiotensin system.
    Chalmers J
    J Hypertens; 2013 Feb; 31(2):261-2. PubMed ID: 23303352
    [No Abstract]   [Full Text] [Related]  

  • 48. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed.
    Wong J
    Diab Vasc Dis Res; 2013 May; 10(3):193-201. PubMed ID: 23349369
    [TBL] [Abstract][Full Text] [Related]  

  • 50. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Angiotensin-converting enzyme inhibitors and renal failure in diabetes.
    Hiremath S; Zimmerman D; Knoll GA
    Kidney Int; 2006 Oct; 70(7):1377; author reply 1378. PubMed ID: 16988744
    [No Abstract]   [Full Text] [Related]  

  • 52. Comparative role of angiotensin receptor blockers versus other agents in the management of hypertension, cardiovascular disease and nephropathy.
    Tempelhof MW
    South Med J; 2009 Dec; 102(12):1201-2. PubMed ID: 20016423
    [No Abstract]   [Full Text] [Related]  

  • 53. Prevention of progression and remission/regression strategies for chronic renal diseases: can we do better now than five years ago?
    Perico N; Codreanu I; Schieppati A; Remuzzi G
    Kidney Int Suppl; 2005 Sep; (98):S21-4. PubMed ID: 16108966
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Dual blockade of the renin-angiotensin system].
    Andersen NH; Mogensen CE
    Ugeskr Laeger; 2004 Oct; 166(43):3799-803. PubMed ID: 15544108
    [No Abstract]   [Full Text] [Related]  

  • 55. Inhibition of the renin-angiotensin system, with particular reference to dual blockade treatment.
    Andersen NH; Mogensen CE
    J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2(3):146-52. PubMed ID: 11881115
    [No Abstract]   [Full Text] [Related]  

  • 56. Do inhibitors of the rennin-angiotensin system prevent chronic kidney disease?
    Rayner B
    Cardiovasc J Afr; 2010; 21(1):3-6. PubMed ID: 20224837
    [No Abstract]   [Full Text] [Related]  

  • 57. Renin-angiotensin system inhibitors in proteinuric chronic kidney disease.
    Hirsch S
    Compr Ther; 2009; 35(2):91-5. PubMed ID: 19618757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The end of the road for dual renin-angiotensin system blockade in diabetic nephropathy: which way now?
    Advani A
    Can J Diabetes; 2014 Oct; 38(5):292-5. PubMed ID: 25172268
    [No Abstract]   [Full Text] [Related]  

  • 59. Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure.
    Nakamura T; Sugaya T; Koide H
    Diabetologia; 2007 Feb; 50(2):490-2. PubMed ID: 17171364
    [No Abstract]   [Full Text] [Related]  

  • 60. [Blockade of the renin-angiotensin system. ACE inhibitors, angiotensin II antagonists or both?].
    Karlsen FM; Kamper AL
    Ugeskr Laeger; 2003 Oct; 165(42):4006-9. PubMed ID: 14610833
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.